Eli Lilly announces 650,000 additional doses of bamlanivimab purchased by US government to treat Covid-19

This article was originally published here

Bamlanivimab recently received emergency use authorization for the treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.

The post Eli Lilly announces 650,000 additional doses of bamlanivimab purchased by US government to treat Covid-19 appeared first on Pharmaceutical Business review.